Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘hair loss drug’

Pradaxa Injury lawyer, Pradaxa Heart Attack, Pradaxa Wrongful Death

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Pradaxa is an anticoagulant with dangerous side effects. Pradaxa has caused heart attacks and wrongul Death. Lawyers accepting Clients who are victims of Pradaxa.

The U.S. Food and Drug Administration (FDA) is evaluating post-marketing reports of serious bleeding events in patients taking Pradaxa (dabigatran etexilate mesylate). Pradaxa is a blood thinning (anticoagulant) medication used to reduce the risk of stroke in patients with non-valvular atrial fibrillation (AF), the most common type of heart rhythm abnormality.

In January of 2012, Boehringer Ingleheim announced safety label changes that had been approved by the FDA3, including the following:

    5 WARNING AND PRECAUTIONS 


    5.1 Risk of Bleeding

        Pradaxa’s anticoagulant activity and half-life are increased in patients with renal impairment.
        Lack of a specific reversal agent; futility of using vitamin K to affect anticoagulant effect

 

On December 7, 2011, the U. S. Food and Drug Administration (FDA) issued a Safety Communication reporting that it was investigating reports of serious and fatal bleeds in patients taking Pradaxa. Injury lawyer Network Pradaxa lawyers are accepting cases for Pradexa.    symptoms of bleeding such as

 Pradaxa has caused serious side effects   

If you are using the blood thinner Pradaxa (dabigatran), you may be at risk of suffering a stroke, or even death from this dangerous drug. If you are suffering any of these side effects see your doctor immediately.

Pradexa side effects

    bleeding which can be serious, and sometimes lead to death
    it may take longer for any bleeding to stop
    unexpected bleeding or bleeding that lasts a long time
    unusual bleeding from the gums
    frequent nose bleeds
    menstrual bleeding that is heavier than normal
    bleeding that is severe or you cannot control
    bruises that happen without a known cause or get larger
    bruising more easily
    coughing up blood or blood clots
    feeling dizzy or weak
    headaches
    pink or brown urine
    red or black stools
    unexpected pain, swelling, or joint pain
    vomiting blood or vomit that looks like "coffee grounds"

Serious Side Effects of Pradaxa®

The FDA approved Pradaxa® in October 2010, for the prevention of strokes in patients with a heart condition called non-valvular atrial fibrillation (also known as "AF"). Thus, it's hardly 'over a year old' as an anticoagulant in the U.S., and some critics of Pradaxa® have contended that the drug wasn't tested thoroughly enough before it was put on the market.

Pradaxa® Internal Bleeding

In November of 2011, a European counterpart to the FDA cited over 250 cases of fatal internal bleeding linked to Pradaxa® (a differently named version of Pradaxa® was on the market in Europe before it was released in the U.S.). The FDA has also received reports of Pradaxa®-associated internal bleeding here in the U.S.

Signs and symptoms of internal bleeding from Pradaxa  include:

    Throwing up blood or vomit that looks like coffee grounds
    Unexplained bleeding or bruising
    Swelling in the ankles, feet, lower legs, hands and/or arms
    Excess fatigue
    Nosebleeds, bleeding from the gums
    Coughing up blood
    Dark colored urine

Pradaxa® and Heart Attacks, Serious Side Effects for Pradexa

Studies have also shown that Pradaxa® may increase the risk of heart attack. In a study of 18,000 patients, it was found that Pradaxa® treatment produces a 38 percent higher risk of heart attack than warfarin, an anticoagulant that has been used for many years.

Class Action Lawyer  Network Pradaxa Team is investigating most serious side effects of Pradaxa including:

    death from severe or excessive bleeding
    gastrointestinal bleeding
    stomach pain (ulcers, nausea, heartburn, bloating)
    kidney failure (kidney bleeding)
    hemorrhagic stroke cerebral hemorrhage
    heart attack
    brain hemorrhaging

If you or a loved one has been seriously  injured by Pradaxa call injury lawyer network Pradexa Helpline today.

Pradaxa may lead to excessive bleeding and other complications that could cause severe injury or even be life threatening. If you or a loved one has taken Pradaxa and experienced complications contact Our Pradaxa  legal team today so that  answer your questions and connect you with a Pradaxa Lawyer  to discuss your potential Pradaxa Lawsuit.

Actos Lawyers, Actos News, Actos Bladder Cancer Victims

Written by Class Action Lawyer on . Posted in Louisiana Multidistrict Litigation Lawyers

Actos has warnings for bladder cancer. Actos cases have been consolidated and Actos Lawyers are accepting clients.

The judge overseeing lawsuits alleging Takeda Pharmaceutical Co. (4502)’s Actos diabetes medicine causes cancer appointed 19 plaintiffs’ lawyers to manage litigation involving U.S. claims.

Takeda, Asia’s biggest drugmaker, may face as many as 10,000 claims that Actos causes bladder cancer after U.S. regulators found last year the drug was linked to the disease. Federal lawsuits against the drugmaker were consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, in December. The first hearing on the cases is set for March 22, according to court filings.

“The court has determined to effect the selection of lead counsel, liaison counsel and plaintiffs’ executive and steering committees before the March 22nd-23rd status conference,” Doherty said in a March 12 note posted on the court’s website.

The lawsuits claim patients who use Actos, a prescription drug approved to treat type 2 diabetes, face increased risks of developing bladder cancer. The plaintiffs also claim that Takeda and co-defendant Eli Lilly & Co., based in Indianapolis, withheld information about the risk and failed to provide adequate warnings.

Takeda pulled Actos, its top-selling drug, off the market in Germany and France last year after it was linked to an increased cancer risk. The medication had sales of 387.9 billion yen ($4.8 billion) last fiscal year, 27 percent of the Osaka, Japan-based company’s revenue.
Lead Counsel

“Given that litigation is pending, we can’t comment,” Jocelyn Gerst, a U.S.-based spokeswoman for Takeda, said in a telephone interview about the selection of the plaintiffs’ group.

Doherty named attorneys Richard Arsenault and Paul Pennock as lead plaintiffs’ counsel in the case and also appointed them to the executive committee, along with lawyers Mark Robinson and Hunter Shkolnik.

Arsenault, a products-liability lawyer based in Alexandria, Louisiana, served as one of the lead lawyers in consolidated cases filed against Merck & Co. (MRK) over its Vioxx painkiller that resulted in a $4.85 billion settlement in November 2007.

Pennock, a New York-based attorney, was one of the lawyers leading the consolidated suits against AstraZeneca Plc (AZN) over its Seroquel antipsychotic drug. The London-based drugmaker agreed last year to pay a total of about $350 million to resolve patients’ claims that the drug caused diabetes.
Steering Committee

The Los Angeles-based Robinson, who has won multimillion- dollar jury awards against carmakers such as Ford Motor Co., is a co-lead counsel in sudden-acceleration lawsuits against Toyota Motor Corp. (7203)

Shkolnik, based in New York City, served as a member of the plaintiffs’ steering committee in lawsuits against Medtronic Inc. (MDT) over flawed heart defibrillators. The cases later settled for more than $114 million.

Other lawyers named to the plaintiffs’ steering committee in the Actos cases include Mark Lanier, a Texas-based lawyer who won the first jury award against Whitehouse Station, New Jersey- based Merck in the Vioxx litigation, and Chris Seeger, a New Jersey-based attorney who also won a verdict against Merck on behalf of Vioxx users.

The judge also named Andy Birchfield, an Alabama-based lawyer who helped negotiate the $4.85 billion Vioxx settlement, and Vance Andrus, a Lafayette-based lawyer who was one of the lead counsels in cases against GlaxoSmithKline Plc (GS) over its Avandia diabetes drug. The London-based drugmaker has agreed to pay more than $700 million to resolve claims that Avandia caused heart attacks and strokes in users.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, 11-2299, U.S. District Court, Western District of Louisiana (Lafayette).

Lawyers Still Accepting Actos Cases, Actos Causing Bladder Cancer

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Lawyers Still Accepting Actos Cases as First Hearing Set to Begin. If you or a loved one has been diagnosed with bladder cancer from Actos contact us for an Actos lawyer today.

10,000 Actos lawsuits are expected to be filed
Orlando, FL (PRWEB) February 21, 2012
A federal judge tasked with overseeing the litigation over whether a popular diabetes drug caused bladder cancer in hundreds of patients is moving quickly to expedite the legal process for both sides.
While those who have already filed an Actos lawsuit are one step closer to having their day in court, lawyers are still helping those who are just coming forward with side effects.
On Monday, February 13, U.S. District Judge Rebecca Doherty issued an order scheduling a pretrial status conference in the Actos litigation for March 22, 2012. The hearing will give representatives of the drug manufacturer and those of patients alleging bladder cancer from the drug a chance to discuss trial preparation and whether any progress has been made in reaching a settlement.
After the hearing, Judge Doherty will also appoint lead counsel in the consolidated cases from her bench in Lafayette, Louisiana.
Doherty was originally assigned to dozens of the lawsuits in Multi-District Litigation following an order by the U.S. Judicial Panel on Multidistrict Litigation in December. She now presides over approximately 150 cases and lawyers expect thousands more may be filed before litigation is complete. The pending case is In Re: Actos Products Liability Litigation, MDL 2299, U.S. District Court, Western District of Louisiana (Lafayette).
Lawyers with the Actos Resource Center have responded to hundreds of inquiries from those who have taken Actos and expect many more will come forward due to the popularity of the drug.
On June 15, 2011, the FDA issued a warning that taking Actos for longer than one year could heighten the risk of bladder cancer. Approved by the FDA in 1999, Actos had become one of the most popular diabetes drugs in the world after rival Avandia was linked to heart problems.
The warning came after a study of 155,000 patients over four years by the French Medicines Agency showed taking Actos could increase the occurrence of bladder cancer by up to 40%.
Authorities in France and Germany quickly banned sales of the drug. However, it remains on the market in the United States.
Now, according to a Bloomberg article published December 1, 2011, drug makers Takeda Pharmaceuticals and Eli Lilly could face as many as 10,000 lawsuits from those stricken with bladder cancer after taking Actos.
On Tuesday, Takeda released a statement saying "Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes twelve years of clinical and patient experience with the product."
For more information on the side effects, FDA warnings and litigation associated with Actos, visit ActosCancer.com.

Class Action Lawyer Netrwork Actos Lawyers are accepting cases for bladder cancer form Actos. These are part of an Actos Multi District litigation.

Actos for causing Bladder Cancer, First Hearing being held

Written by Class Action Lawyer on . Posted in Drug Lawsuits

Actos has been shown to cause bladder cancer. First hearing being held for Actos and Class Action Lawyer Nework Actos Lawyers are accepting new cases.

 

(AP)  NEW ORLEANS — A federal judge in Louisiana has scheduled an initial court hearing for a batch of lawsuits that claim Takeda Pharmaceuticals' top-selling diabetes drug, Actos, carries an increased risk of bladder cancer.

In an order issued Monday, U.S. District Judge Rebecca Doherty said she plans to appoint lead attorneys for the consolidated cases after the March 22 status conference in her Lafayette, La., courtroom.

In December, the U.S. Judicial Panel on Multidistrict Litigation assigned Doherty to preside over dozens of lawsuits against Actos maker Takeda Pharmaceuticals America Inc., which is based in Deerfield, Ill. Plaintiffs' attorneys expect to file several thousand claims against Takeda and its related companies on behalf of people who used the drug.

Takeda's Japanese parent company, Takeda Pharmaceuticals Co. Ltd., halted sales of Actos in Germany and France last year. The U.S. Food and Drug Administration issued a warning about the drug's possible cancer risks in 2010 but allowed sales to continue.

After the FDA approved Actos in 1999, Takeda co-promoted the drug in the U.S. with Eli Lilly & Co. Takeda took over responsibility for the drug's marketing when the agreement between the company ended in 2006, attorneys for the companies said in court papers.

An FDA spokeswoman says information about a possible risk of bladder cancer associated with the use of Actos has been on its label since the drug was approved for treating Type 2 diabetes in 1999.

Takeda released a statement on Tuesday saying that it works hard to evaluate any potential risks associated with its products.

"Takeda is confident in the therapeutic benefits of Actos and its importance as a treatment for type 2 diabetes. As a science and evidence-based company, Takeda firmly stands behind the substantial data available confirming the positive risk/benefit profile of Actos, which includes twelve years of clinical and patient experience with the product," the statement said.

The first lawsuit linking Actos to bladder cancer was filed against Takeda and Eli Lillly in July 2011, according to the companies' lawyers.

Paul Pennock of Weitz & Luxenberg, a New York firm that represents dozens of people with Actos-related claims, said Judge Doherty is now handling roughly 150 of these suits. Thousands more could have federal claims filed in or transferred to Lafayette by the end of the year, he said.

"People should not run the risk of getting bladder cancer from treating their diabetes given the many other excellent therapies available," Pennock said.

Thousands of other claims involving Actos are expected to be heard in California and Illinois state courts.

The lawsuits claim researchers have found that people who take Actos for more than a year are at increased risk of developing bladder cancer. The suits also accuse Takeda of concealing their knowledge of the cancer risks and failing to adequately warn consumer and health care providers.

Actos sales in the U.S. fell by roughly 3 percent last year, but the drug remained the best-selling Type 2 diabetes drug on the market, according to the health care information firm IMS Health. The firm says Actos accounted for $3.4 billion in sales in 2011, or nearly 84 percent of sales among drugs in the same class.

Class action layers of Class Action lawyer Network are accepting cases of bladder cancer form Actos. Multi District litgation filed

Propecia Multi District Litigation

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Federal Panel to Decide on Propecia Multidistrict Litigation in 2012
Ryan Green | January 24th, 2012 | Posted in Propecia Lawsuit News

A panel of federal judges are about to decide whether to designate Propecia multidistrict litigation (MDL) for cases in which plaintiffs seek damages for alleged Propecia side effects. If MDL is implemented, each Propecia lawsuit filed in any federal court across the country will be transferred to a single courthouse for consolidated pretrial proceedings.

Defendant Merck, the manufacturer of the hair loss drug, has requested that Propecia side effects cases be transferred to New Jersey for MDL. Other possible venues are New York or Washington State.
Propecia side effects may last longer than initially thought

Research shows that even as Propecia (finasteride) can lead to increased hair growth it can also lead to decreased sexual function. Propecia side effects that have formed the basis of a Propecia lawsuit include erectile dysfunction, libido loss, decreased ejaculate, breast tenderness, testicular pain, depression and prostate cancer.

A 2011 Boston University School of Medicine study found that Propecia side effects could occur more frequently than initially thought, including, in the case of sexual dysfunction, at a rate of  8%. Furthermore, another study published in the Journal of Sexual Medicine found that Propecia side effects may persist after a man has stopped taking the drug and may even be permanent.
Propecia lawsuit may help plaintiffs get compensation for injuries

Many men suffering debilitating Propecia side effects are pursuing compensation through a Propecia lawsuit. In addition to cases filed in federal court, other cases have been filed in state courts. Regardless of where it is filed, a Propecia lawsuit generally alleges that Merck is responsible for injuries caused by the drug because the company knew or should have known about Propecia side effects, but failed to warn consumers.

The question asked by Propecia litigation is: How many men, if they had been adequately informed of the risks, would trade sexual function for a fuller head of hair?
Lawsuits likely to be consolidated in Propecia multidistrict litigation

As long as all the Propecia side effects cases filed in federal courts involve a common question of fact, they can be consolidated into multidistrict litigation (MDL) for pretrial proceedings. The U.S. Judicial Panel on Multidistrict Litigation makes the decision about whether to consolidate cases into an MDL based on convenience and efficiency. The goal is to avoid duplicative discovery, prevent inconsistent rulings and conserve resources.

One Propecia lawsuit plaintiff has requested that the Propecia multidistrict litigation be sent to the U.S. District Court for the Eastern District of New York or to the Western District of Washington.

Merck, on the other hand, has requested that the MDL be transferred to New Jersey, where the majority of Propecia side effects cases have been filed. New Jersey is also where Merck is headquartered.

The next hearing on Propecial multidistrict litigation is on March 29, 2012 in San Diego.Class Action lawyer Network Procpecia lawyers and Multi dostrict litigation lawyers aere accepting propecia clients.